Replies to post #237703 on Biotech Values

[DewDiligence]

PFE has Sasanlimab*, an in-house PD-1 agent that can be given subcutaneously (see slide #19 from Sep 2020 presentation):

https://t.co/b5M9okPr1Q?amp=1

*a/k/a PF-06801591.